ResolutionMD Receives Class II Certification for Japanese Market

vital biometrics and wearable techCalgary Scientific’s flagship medical imaging software system has received a major new certification for clinical use. The ReolutionMD platform has now been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), receiving a Class II certification.

The platform essentially lets medical professionals use mobile devices to offer clinical diagnoses by analyzing the secure medical images it displays. According to Calgary Scientific, it’s already in use around the world, with over 45 major healthcare partners participating. Getting this accreditation in Japan should help medical professionals there to embrace the platform too; speaking in a press release, Calgary Scientific President and CTO Pierre Lemire said he is “pleased that ResolutionMD can now be used in Japan, enabling practitioners to make faster, more informed treatment decisions in their pursuit to deliver a new standard of patient care.”

The new certification follows pretty closely in the wake of the platform’s approval for the Australian healthcare system last November, and also on the heels of the company’s win in December as the 2014 North American Frost & Sullivan Award for Growth Capital Investment Opportunity. Recently the company has been touting ResolutionMD as a solution to help manage the complicated practical issues that can arise when hospitals merge, as they are increasingly doing to cut costs. That could prove appealing in Japan’s healthcare market, which is facing daunting demographic challenges in the years ahead.